Seroatlas · Human Serome Atlas

IL22RA2

Interleukin-22 receptor subunit alpha-2

Also known as: CRF2-S1, I22R2_HUMAN, IL-22BP

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q969J5
Gene: IL22RA2
Ensembl: ENSG00000164485
Chromosome: 6
Canonical length: 263 aa
Protein class: Predicted secreted proteins
Secretome location: Secreted to blood

OverviewNCBI Gene

This gene encodes a member of the class II cytokine receptor family. The encoded soluble protein specifically binds to and inhibits interleukin 22 activity by blocking the interaction of interleukin 22 with its cell surface receptor. The encoded protein may be important in the regulation of inflammatory response, and has been implicated in the regulation of tumorigenesis in the colon. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

263 residues, UniProt reviewed canonical sequence.

>Q969J5|IL22RA2
     1  MMPKHCFLGF LISFFLTGVA GTQSTHESLK PQRVQFQSRN FHNILQWQPG RALTGNSSVY
    61  FVQYKIMFSC SMKSSHQKPS GCWQHISCNF PGCRTLAKYG QRQWKNKEDC WGTQELSCDL
   121  TSETSDIQEP YYGRVRAASA GSYSEWSMTP RFTPWWETKI DPPVMNITQV NGSLLVILHA
   181  PNLPYRYQKE KNVSIEDYYE LLYRVFIINN SLEKEQKVYE GAHRAVEIEA LTPHSSYCVV
   241  AEIYQPMLDR RSQRSEERCV EIP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against IL22RA2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.37
Highest tissue expression: 3.4 nTPM

Expression across tissuesHPA

Tissue

breast: 3.4 nTPM
tonsil: 3 nTPM
appendix: 1.3 nTPM
lymph node: 1.1 nTPM
spleen: 1 nTPM
skin: 0.5 nTPM

Single-cell type

breast secretory cells: 5.6 nCPM
syncytiotrophoblasts: 3.4 nCPM
macrophages: 2.3 nCPM
monocytes: 2.3 nCPM
neutrophils: 1.8 nCPM
breast hormone-responsive cells: 1.3 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

amygdala: 0 nTPM
basal ganglia: 0 nTPM
cerebellum: 0 nTPM
cerebral cortex: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.86
gnomAD pLI: 0
gnomAD missense Z: -0.14
DepMap mean gene effect: 0.04
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads IL22RA2 as an antibody target. Whether an autoantibody or antibody against IL22RA2 could matter depends on whether native IL22RA2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

IL22RA2 is annotated as secreted, so native IL22RA2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label IL22RA2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...